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Background: Global developmental delay and mental retardation are associated with X-linked disorders including
Hunter syndrome (mucopolysaccharidosis type II) and Fragile X syndrome (FXS). Single nucleotide mutations in the
iduronate 2-sulfatase (IDS) gene at Xq28 most commonly cause Hunter syndrome while a CGG expansion in the
FMR1 gene at Xq27.3 is associated with Fragile X syndrome. Gene deletions of the Xq27-28 region are less
frequently found in either condition with rare reports in females. Additionally, an association between Xq27-28
deletions and skewed X-inactivation of the normal X chromosome observed in previous studies suggested a
primary role of the Xq27-28 region in X-inactivation.
Case presentation: We describe the clinical, molecular and biochemical evaluations of a four year-old female
patient with global developmental delay and a hemizygous deletion of Xq27.3q28 (144,270,614-154,845,961 bp), a
10.6 Mb region that contains >100 genes including IDS and FMR1. A literature review revealed rare cases with
similar deletions that included IDS and FMR1 in females with developmental delay, variable features of Hunter
syndrome, and skewed X-inactivation of the normal X chromosome. In contrast, our patient exhibited skewed
X-inactivation of the deleted X chromosome and tested negative for Hunter syndrome.
Conclusions: This is a report of a female with a 10.6 Mb Xq27-28 deletion with skewed inactivation of the deleted X
chromosome. Contrary to previous reports, our observations do not support a primary role of the Xq27-28 region in
X-inactivation. A review of the genes in the deletion region revealed several potential genes that may contribute to
the patient’s developmental delays, and sequencing of the active X chromosome may provide insight into the
etiology of this clinical presentation.
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X-linked mental retardationBackground
Hunter syndrome (mucopolysaccharidosis type II; MIM
309900) and Fragile X syndrome (FXS; MIM 300624)
are two X-linked disorders that can cause developmental
delays and are infrequently found in females. In Hunter
patients, dysfunction or absence of the iduronate-2-sul-
fatase (IDS) enzyme leads to the accumulation of muco-
polysaccharides heparin sulfate and dermatan sulfate [1].
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reproduction in any medium, provided the or(IDS) gene at Xq28 most commonly cause Hunter syn-
drome but deletion of the IDS gene has been reported in
Hunter patients [2-4]. Fragile X syndrome is usually as-
sociated with the expansion of the CGG trinucleotide re-
peat in FMR1 at Xq27.3 region [5,6], deletion of FMR1
has also been reported in males with Fragile X [7-10].
The Xq27-28 region, which contains IDS and FMR1,
may also play a role in X-inactivation. Previous studies
reported skewed X-inactivation in females with mental
retardation and deletions within this region [11-15]. In
this report, we describe a female patient with global de-
velopmental delays and a ~10.6 Mb deletion at Xq27.3-
q28 (144,270,614-154,845,961 bp), a region that contains
more than 100 genes including IDS and FMR1. X-
inactivation studies and IDS activity assays werel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Contrary to previous reports, our results do not support
a role of the Xq27-28 region in X-inactivation.
Case presentation
Clinical summary
The patient is a four year-old female who presented at
age 23 months to the Medical Genetics clinic with global
developmental delays of unknown cause. She was born
to a 29-year-old gravida IV, para III mother (x1 spontan-
eous abortion) and a 36-year-old father, both of Mexican
ethnic background. At three months gestation her
mother had a cholecystectomy and received morphine.
At full term gestation, the patient was born by normal
spontaneous vaginal delivery with no complications and
was discharged the next day. Her birth weight was 7 lbs
and 9 ounces (50th-75th percentile) and birth length
was 21 inches (90th percentile).
The parents report that her delays in development
were first noticed around age five months. At age nine
months, the infant was diagnosed with global develop-
mental delay and hypotonia. She began to crawl at
12 months and to sit on her own at 15 months. At the
age of 22 months, neurological and formal developmen-
tal assessments were conducted at the Stramski Chil-
dren’s Developmental Center in Long Beach, CA. The
patient was assessed using the Bayley Scales of Infant
Development (BSID III) and the relative chronological
ages for the following developmental domains were as
follows: cognitive (11 months), receptive language
(3 months), expressive language (6 months), fine motor
(15 months), and gross motor (11 months). The patient
did not meet the diagnostic criteria for autism.
At age 23 months old, she was evaluated in the Med-
ical Genetics clinic (MVZ and JS). Physical examination
(Figure 1) showed that the patient had wide eye fissures,
down turned corners of the lips, full cheeks, temporal
narrowing, gaps between her teeth and long eyelashes.
Her fingers were tapered with a hypoplastic distal crease
of her left index finger, and she wore corrective lenses
for myopia. She had limited speech and mild centralFigure 1 Facial Features. Front (A), three-quarter (B), and profile (C) viewhypotonia. Detailed pedigree analysis showed that she
has healthy parents, two older siblings (a 14-year-old
maternal half-brother and a 3-1/2-year-old full sister),
and two paternal first cousins with autism and Asperger
syndrome. There was no known consanguinity.
At the age of 31 months, follow-up development as-
sessment by HELP Strands tests suggested global delays.
The age equivalence was determined in the following
skill domains: cognition (11–16 months), receptive lan-
guage (8–13 months), expressive language/communica-
tion (6–9 months), gross motor (13–15 months), fine
motor (13–16 months), social emotional (9–12 months),
and self health (12–17 months). She was re-tested using
BSID III and exhibited global development delays in
both cognitive (percentile rank= 1) and language abilities
(percentile rank= 0.1). At 31 months her relative
chronological ages for the following developmental do-
mains were as follows: cognitive (18 months), receptive
language (9 months), expressive language (9 months),
fine motor (20 months), gross motor (15 months).
Additional clinical evaluations included a normal elec-
troencephalogram and brain MRI studies at age
31 months, normal electrocardiogram and echocardiog-
raphy studies at age 3 years 5 months, and normal bone
contour and density by radiographical skeletal survey at
age 3 years 6 months.
At her last follow-up clinic visit at age 4 years-9-months
old, the patient is making progress and no history of sei-
zures or regression. Her parents report that recently she
has displayed a greater sense of understanding when
others communicate with her. She also points and uses
her hands to communicate when she wants something.
She has mild muscular hypotonia and her growth parame-
ters are normal for her age.
Molecular and biochemical studies
To investigate a genetic cause for the patient’s global de-
velopmental delays, blood chromosome analysis, DNA
analysis for Fragile X syndrome, and Clarisure BAC
array comparative genomic hybridization (CGH) studies
were performed at Quest Diagnostics (San Juans of the patient.
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included quantitative serum lactate, pyruvate and creat-
ine phosphokinase (CPK), quantitative urine organic
acids and plasma amino acids at St. Louis University
Metabolic Screening Lab (St. Louis, MO). Urine bio-
chemical studies for mucopolysaccharides (MPS) were
performed at Quest Diagnostics (San Juan Capistrano,
CA) and the Greenwood Genetic Center (Greenwood,
South Carolina). IDS enzymatic assay and X-inactivation
study of blood samples were performed by the Green-
wood Genetic Center. The androgen receptor locus
(HUMARA) at Xq12 was used to study X-inactivation
[16]. The ratio of active to inactive X chromosome was
determined by PCR analysis examining DNA methylation-
sensitive restriction enzyme sites near the polymor-
phic CAG repeat in first exon of HUMARA [16].
Molecular studies for the patient’s parents included
Fragile X PCR and Southern Blot analysis and Oligo-
nucleotide SNP array studies and were performed by
Quest Diagnostics (San Juan Capistrano, CA). Details
of the BAC and Oligonucleotide SNP arrays are avai-
lable at www.questdiagnostics.com.
Deletion region detected at Xq27.3q28
Chromosome and DNA studies found an abnormal
karyotype with a deletion on the X chromosome. Fragile
X PCR revealed only one unmethylated FMR1 allele
within the normal size range (~30 CGG repeats), and
Southern Blot analysis confirmed a deletion of the FMR1
region on one X chromosome. BAC array showed a
~10.6 megabase deletion at Xq27.3q28 (144,270,614-
154,845,961 bp) encompassed within BAC clones CTD-
3109C8 to CTD-2341N11 (Figure 2). This deletion
resulted in hemizygosity for 113 RefSeq genes including
the FMR1 and iduronate 2-sulfatase (IDS) genes which
are associated with Fragile X syndrome (FXS) and
Hunter syndrome, respectively (Figure 3). OMIM
disease-associated genes within the deletion region in-
cluded: FMR1, AFF2 (FMR2), IDS, MAMLD1, MTM1,Figure 2 Array CGH ratio plot depicts ~10.6 Mb at Xq27.3-q28. Deletio
for >100 genes including FMR1 and iduronate 2-sulfatase (IDS). BAC probes
Array was performed using Clarisure CGH by Quest Diagnostics.NSDHL, ATP2B3, FAM58A, SLC6A8, ABCD1, L1CAM,
AVPR2, NAA10, HCFC1, MECP2, OPN1LW, OPN1MW,
FLNA, EMD, RPL10, TAZ, GDI1, G6PD, IKBKG
(NEMO), DKC1, F8, RAB39B, CLIC2, and TMLHE.
Parental FMR1 PCR and Southern Blot analysis
revealed ~30 and 31 repeats for the mother and ~31 re-
peats for the father. Oligonucleotide SNP arrays were
normal for both parents. These findings indicate that the
deletion was a de novo event (Table 1).Skewed X-inactivation studies and negative biochemical
studies for Hunter syndrome
Normal results were obtained for serum lactate, pyruvate
and creatine phosphokinase (CPK), quantitative urine
organic acids and plasma amino acids. Initial quantita-
tive urine analysis found elevated levels of mucopolysac-
charides (17.5 mg/mmol creatinine; reference range=
<16.0 mg mg/mmol creatinine) at age 3 years-old. How-
ever, repeat urine studies at age 3 years 10 months-old
found normal quantitative (6.97, normal less than 16)
and qualitative urine MPS studies.
The peripheral blood samples tested normal for IDS
activity (808 nmol 4MU released/hr/ml plasma; normal
range= 182–950 4MU released/hr/ml plasma). The
HUMARA X-inactivation studies showed two alleles
with PCR lengths of 287 and 299 base pairs that corres-
pond to CAG repeat lengths of 22 and 26 repeats, re-
spectively. Methylation analysis showed that the 287
PCR fragment (22 repeats) was methylated correspond-
ing to an X-inactivation ratio of 100:0, indicating highly
skewed X-inactivation. Because IDS is found within the
deletion region and we assume that our patient only has
one functional copy of the gene, then the functioning
IDS gene must be on the preferentially active X chromo-
some and the deletion region must be on the inactive X
chromosome. Therefore, we concluded that the X
chromosome with the deletion region was preferentially
inactivated (Table 1).n region is highlighted in red. The deletion resulted in hemizygosity



















































Figure 3 Schematic of X chromosome and genes in the Xq27.3-q28 region. Region of deletion is highlighted by the red box. Shown are the
OMIM-disease associated genes in green and all RefSeq genes in blue within the deletion region of 144,270,614-154,845,961 bp (hg19). Image
was adapted from http://genome.ucsc.edu/cgi-bin/hgTracks.
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We report a four year-old female patient with global de-
velopmental delay, hypotonia, and a ~10.6 Mb hemizy-
gous deletion of Xq27.3q28. To determine the specific
cause of her condition, we conducted biochemical and
X-inactivation studies on the proband and molecular
studies on the parents. There are over 100 genes (113
RefSeq and 29 OMIM disease-associated genes) cur-
rently described within the deletion region, and we con-
sidered a number of the associated conditions and the
potential role of unbalanced X-inactivation as a genetic
mechanism for our patient’s condition.
Hunter syndrome was initially considered as a poten-
tial diagnosis because the iduronate 2-sulfatase (IDS)
gene was located in the deletion region and if it did turn
out that Hunter syndrome was the cause of her condi-
tion, we could offer our patient therapy through enzyme
replacement. IDS deletions are found in some Hunter
syndrome patients [2-4,17], and a more severe Hunter
phenotype has been reported in patients with larger de-
letion regions that include FMR1 [17]. Additionally, it
was found that a female Xq27-28 deletion patient with
Hunter syndrome [11] had unbalanced X chromosome
inactivation in which the normal X chromosome was
preferentially inactivated. However, unlike Clarke’s pa-
tient [11], our patient lacked the typical features for stor-
age diseases including macrocephaly, coarse features,
hepatomegaly, cardiac and skeletal abnormalities [18].
Nevertheless, we pursued the diagnosis when her initial
urine analysis revealed a mild elevation of muco-Table 1 Summary of results
Test Patient




*Based on BAC array for patient and Oligonucleotide SNP array for parents; n.d., nopolysaccharides. However, repeat studies found normal
mucopolysaccharide levels and distribution and IDS en-
zymatic assay in blood leukocytes was normal. Thus, the
diagnosis of Hunter syndrome was excluded in our pa-
tient. Additionally, the positive IDS assay suggested that
the functional IDS gene was located on the active X
chromosome; therefore we made the assumption that
the deletion region was located on the inactive X
chromosome.
We next considered other X-linked mental retardation
conditions including Fragile X syndrome as the FMR1
gene is also located in the deletion region and FMR1 de-
letions are associated with Fragile X syndrome [7-10].
Following Clarke et al., 1992, at least three additional
deletion Xq27 or Xq27-28 females with hemizygosity for
FMR1 have been reported [12-15]. Similar to our pa-
tient, these females had non-specific characteristics of
Fragile X syndrome such as hypotonia, speech, motor,
and language delays, and cognitive impairment [19].
Two of the patients also had unbalanced X-inactivation
of the normal X chromosome; thus, at least partial loss
of FMR1 or other genes within the deletion may contrib-
ute to their phenotype [13-15]. However, in contrast to
these previous reports, our patient had preferential in-
activation of the deleted X-chromosome and a normal
sized and unmethylated FMR1 allele, and the diagnosis
of Fragile X syndrome was also excluded.
It is possible that the large size of the deletion in our
patient may explain the highly skewed inactivation pat-
tern. Compared to previous Xq27-28 deletion femalesFather Mother
x1 Normal Normal
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including practically all of Xq28. Highly skewed inactiva-
tion pattern has been observed in patients with gene
mutations within the Xq28 region due to negative cell
selection. For example, skewed inactivation has been
reported in rearrangement and truncation mutations
that result in a loss of function in the NEMO (IKBKG)
gene, which is associated with incontinentia pigmenti,
hypohidrotic ectodermal dysplasia, and other types of
immunodeficiencies [20-22]. In our patient, negative se-
lection of cells expressing the mutant NEMO allele on
the deleted X-chromosome may then result in the highly
skewed X-inactivation; however, this alone cannot ex-
plain her clinical phenotype.
Additionally, significant variation in X-chromosome
inactivation patterns have been found in different tissue
types [23,24]. In particular, in patients with differences
between tissues, peripheral blood was consistently
skewed with greater than 75% expression of one
chromosome [23]. Therefore, our X-inactivation analysis
on blood leukocytes may not be representative of all tis-
sues, and we could consider additional X-inactivation
studies on other tissue types in order to better under-
stand our patient’s gene expression profile.
Another aspect of X-inactivation to consider is
whether any of the genes implicated in our patient’s con-
dition escape X-inactivation. Approximately 10% of X-
linked genes show variation in escape in vitro and a clus-
ter of these genes is found in the Xq28 region [25]. If
some of the genes that normally escape X-inactivation
are within our patient’s deletion region, then hap-
loinsufficiency could account for our patient’s observed
phenotype. Several genes within the Xq28 region ap-
pear to escape X-inactivation, but we found that none
of these genes are related to our patient’s phenotype
[25]. Furthermore, Carrel and Willard (2005) found
that IDS, MTM1, and MECP2 were not expressed from
any of the inactivated X chromosomes, and FMR1 was
expressed in only one out of nine inactive X chromo-
some samples [25]. Therefore, it does not appear as
though that the deletion of these genes would have an
adverse effect since they would not normally be ex-
pressed from an inactivated X chromosome. Neverthe-
less, the extent to which these findings can be applied
to our case study is somewhat limited as the results
were obtained in vitro from fibroblast cells and may not
reflect the in vivo expression or expression in different
tissues.
A final alternative cause of our patient’s phenotype
may be an unknown, additional mutation on the active
normal X-chromosome. Over 100 genes on the X
chromosome have been associated with syndromic and
non-syndromic X-linked intellectual disabilities [26]. An
estimated 40% of the protein-coding genes on the Xchromosome are expressed in the brain and mutations
in these genes have the potential to cause mental retard-
ation [27]. In addition to IDS and FMR1, a literature re-
view revealed several genes within our patient’s deletion
region- SLC6A8, MECP2, GDI1, CLIC2, HCFC1,
RAB39B, and MTM1- that play a role in physical and
mental development. Hahn et al. (2002) report that the
mutation of the creatine-transporter (SLC6A8) gene was
found in patients with mild retardation and other behav-
ioral problems, and Rosenberg et al. (2004) described
one patient with X-linked mental retardation that coin-
cided with a large deletion of the SLC6A8 and other pa-
tients with missense mutations of the gene [28,29].
Partial or complete loss of function mutations of the
MECP2 gene has been associated with mental retard-
ation and Rett syndrome [30]. Other X-linked forms of
mental retardation have been reported in patients with
mutations in GDI1 [31], CLIC2 [32], HCFC1 [33], and
RAB39B [34]. The deletion of MTM1 gene may be asso-
ciated with our patient’s hyptonia as MTM1 deletions
and mutations have been shown to be related to
myotubular myopathy [35]. Additionally, premature
ovarian failure has been reported in patients with dele-
tions within the Xq26.2-q28 region [36], and will be im-
portant to consider as part of the long-term care of our
patient.
Based on the highly skewed X-inactivation pattern ob-
served in our patient, mutations in the active X chromo-
some are especially important to consider as potential
causes of her etiology. Specific conditions and their asso-
ciated genes in Xq27-28 that require investigation in-
clude FRAXE syndrome- FMR2, Rett syndrome-MECP2,
X-linked Mental retardation-41-GDI1, Creatine deficiency
syndrome-SLC6A8, X-linked mental retardation-72-RAB3
9B and X-linked adrenoleukodystrophy-ABCD1.Conclusions
In summary, we report a female with global develop-
mental delay, hypotonia, and a ~10.6 Mb hemizygous
deletion of Xq27.3q28. Biochemical, molecular and X-
inactivation studies failed to support the diagnosis of
Hunter syndrome or Fragile X syndrome. In contrast to
previously reported deletion females, the deleted X-
chromosome was preferentially inactivated. Our results
do not support a primary role of the Xq27-28 region in
X-inactivation. In addition, given that this region is often
involved in genomic rearrangements, we might speculate
that the breakpoint region may contain highly repetitive
DNA sequences that predispose to abnormal recombin-
ation [37]. Future studies may include high-throughput
sequencing of the normal X chromosome, analysis of the
deletion breakpoints, and X-inactivation studies on dif-
ferent tissues to understand the specific mechanism for
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rier female.
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